NO145098B - ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOINDOLIN DERIVATIVES - Google Patents
ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOINDOLIN DERIVATIVES Download PDFInfo
- Publication number
- NO145098B NO145098B NO763225A NO763225A NO145098B NO 145098 B NO145098 B NO 145098B NO 763225 A NO763225 A NO 763225A NO 763225 A NO763225 A NO 763225A NO 145098 B NO145098 B NO 145098B
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- cyclopentyl
- butylamine
- carbon atoms
- methoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title description 4
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 150000007522 mineralic acids Chemical group 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000007514 bases Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- -1 and R4 and R Chemical group 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 15
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 9
- 238000009835 boiling Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 4
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 2
- CIDTUGIPHMXGPB-UHFFFAOYSA-N 2-(3-methoxyphenyl)butanenitrile Chemical compound CCC(C#N)C1=CC=CC(OC)=C1 CIDTUGIPHMXGPB-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VTOQFOCYBTVOJZ-UHFFFAOYSA-N 3-bromopentane Chemical compound CCC(Br)CC VTOQFOCYBTVOJZ-UHFFFAOYSA-N 0.000 description 2
- SHOJXDKTYKFBRD-UHFFFAOYSA-N 4-Methyl-3-penten-2-one, 9CI Chemical compound CC(C)=CC(C)=O SHOJXDKTYKFBRD-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- HWBLTYHIEYOAOL-UHFFFAOYSA-N Diisopropyl sulfate Chemical compound CC(C)OS(=O)(=O)OC(C)C HWBLTYHIEYOAOL-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 2
- 229940008406 diethyl sulfate Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OZXIZRZFGJZWBF-UHFFFAOYSA-N 1,3,5-trimethyl-2-(2,4,6-trimethylphenoxy)benzene Chemical compound CC1=CC(C)=CC(C)=C1OC1=C(C)C=C(C)C=C1C OZXIZRZFGJZWBF-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical class C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 1
- WDKGYAPFDUQMLD-UHFFFAOYSA-N 2-(3-methoxyphenyl)pentanenitrile Chemical compound CCCC(C#N)C1=CC=CC(OC)=C1 WDKGYAPFDUQMLD-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- BLGVDCMNIAOLHA-UHFFFAOYSA-N 2-bromo-3-methylbutane Chemical compound CC(C)C(C)Br BLGVDCMNIAOLHA-UHFFFAOYSA-N 0.000 description 1
- IUXIOXCOPJFKMQ-UHFFFAOYSA-N 2-bromo-4-methylpentane Chemical compound CC(C)CC(C)Br IUXIOXCOPJFKMQ-UHFFFAOYSA-N 0.000 description 1
- UPSXAPQYNGXVBF-UHFFFAOYSA-N 2-bromobutane Chemical compound CCC(C)Br UPSXAPQYNGXVBF-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 229910000761 Aluminium amalgam Inorganic materials 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 150000007962 benzene acetonitriles Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- TWXDDNPPQUTEOV-UHFFFAOYSA-N hydron;n-methyl-1-phenylpropan-2-amine;chloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- SDQCGKJCBWXRMK-UHFFFAOYSA-N propan-2-yl 4-methylbenzenesulfonate Chemical compound CC(C)OS(=O)(=O)C1=CC=C(C)C=C1 SDQCGKJCBWXRMK-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/08—Preparation of carboxylic acids or their salts, halides or anhydrides from nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/54—Preparation of carboxylic acid anhydrides
- C07C51/56—Preparation of carboxylic acid anhydrides from organic acids, their salts, their esters or their halides, e.g. by carboxylation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Fremgangsmåte til fremstilling av nye, terapeutisk virksomme feiiylålkylaminer. Process for the production of new, therapeutically effective phenylalkylamines.
Oppfinnelsen vedrører en fremgangsmåte til fremstilling av nye fenylalkylaminer som utmerker seg ved analgetiske The invention relates to a process for the production of new phenylalkylamines which excel in their analgesic properties
egenskaper. properties.
Det ble funnet at fenylalkylaminer It was found that phenylalkylamines
med den generelle formel with the general formula
hvori R, betyr et hydrogenatom, en lav-molekylær alkylgruppe eller benzylgrup-gen, R2 betyr en alkylgruppe med 2—4 karbonatomer, R;1 betyr en pentyl- eller cyklopentylgruppe, og R4 og R, alkylgrupper med 1—4 karbonatomer eller sammen med det sentrale karbonatom betyr ledd av et mettet rihgsystem med 5—6 karbonatomer, samt salter herav har verdifulle tera-peutiske egenskaper, spesielt analgetisk virkning, og at man får disse forbindelser idet et amin med den generelle formel in which R1 means a hydrogen atom, a low-molecular alkyl group or benzyl group, R2 means an alkyl group with 2-4 carbon atoms, R;1 means a pentyl or cyclopentyl group, and R4 and R, alkyl groups with 1-4 carbon atoms or together with the central carbon atom means members of a saturated ring system with 5-6 carbon atoms, as well as salts thereof have valuable therapeutic properties, especially analgesic action, and that one obtains these compounds as an amine with the general formula
hvori Rj — R:) har den angitte betydning, where Rj — R:) has the indicated meaning,
enten either
a) reduseres med aktivert hydrogen i a) is reduced with activated hydrogen i
nærvær av et keton av den generelle formel presence of a ketone of the general formula
hvori R,, betyr en alkylgruppe med 1—4 karbonatomer og R7 betyr en mettet eller umettet hydrokarbonrest med inntil 4 karbonatomer, eller hvori R,, og R7 sammen med det sentrale karbonatom betyr ledd av et mettet ringsystem med 5—6 karbonatomer, eller b) omsettes med en ester med den generelle formel hvori R4 og Rn har den angitte betydning, og X betyr en uorganisk eller organisk syrerest, hvis ønsket ved hjelp av syre-restavspaltende midler, eller c) oppvarmes med en alkohol med den generelle formel in which R,, means an alkyl group with 1-4 carbon atoms and R7 means a saturated or unsaturated hydrocarbon residue with up to 4 carbon atoms, or in which R,, and R7 together with the central carbon atom means members of a saturated ring system with 5-6 carbon atoms, or b) reacted with an ester of the general formula in which R4 and Rn have the indicated meaning, and X means an inorganic or organic acid residue, if desired with the aid of acid-residue decomposing agents, or c) heated with an alcohol of the general formula
hvori R4 og Rs har den angitte betydning, wherein R 4 and Rs have the indicated meaning,
og hvis ønsket når i fremgangsmåteproduktene substituenten Ri betyr en al- and if desired when in the process products the substituent Ri means an al-
kylgruppe, avspaltes denne etter de vanlige metoder, eller hvis R, betyr et hydrogenatom, overføres hydroksygruppen i al-koksygruppen, eller hvis R, betyr benzylgruppen, avspaltes benzylresten ved katalytisk hydrering, og videre hvis ønsket overføres de dannede basiske forbindelser med uorganiske eller organiske syrer i de tilsvarende addisjonssalter. cooling group, this is cleaved off according to the usual methods, or if R, means a hydrogen atom, the hydroxy group is transferred in the alkoxy group, or if R, means the benzyl group, the benzyl residue is cleaved off by catalytic hydrogenation, and further, if desired, the formed basic compounds are transferred with inorganic or organic acids in the corresponding addition salts.
For fremstilling av fremgangsmåteproduktene er omsetningen av et amin med den generelle formel II med keton av den generelle formel III spesielt godt egnet. For the preparation of the process products, the reaction of an amine of the general formula II with a ketone of the general formula III is particularly well suited.
Alkylrestene R2, R4 og Rr, kan være like eller forskjellige, rettlinjede eller for-grenede. Det kan eksempelvis nevnes me-tyl-, etyl-, n-propyl-, isopropyl-, n-butyl-, isobutyl- og sekundære butylrester. The alkyl radicals R2, R4 and Rr can be the same or different, linear or branched. Mention may be made, for example, of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and secondary butyl residues.
Som aminer kan eksempelvis anvendes: 2- (3'-hydroksy-f enyl) -2-pentyl- (3") - As amines can be used, for example: 2-(3'-hydroxy-phenyl)-2-pentyl-(3") -
butylamin-(l), 2- (3'-hydroksy-f enyl) -2-pentyl- (3") - butylamine-(1), 2-(3'-hydroxy-phenyl)-2-pentyl-(3")-
pentylamin-(l), pentylamine-(l),
2- (3'-hydroksy-f enyl) -2-pentyl- (3") - 2-(3'-hydroxy-phenyl)-2-pentyl-(3")-
3-metyl-butylamin- (1), 3-methyl-butylamine-(1),
2- (3'-hydroksy-f enyl) -2-pentyl- (3") - 2-(3'-hydroxy-phenyl)-2-pentyl-(3")-
3-metyl-pentylamin-(l), 3-methyl-pentylamine-(l),
2- (3'-metoksy-f enyl) -2-pentyl- (3") - 2-(3'-methoxy-phenyl)-2-pentyl-(3")-
butylamin-(l), butylamine-(l),
2- (3'-metoksy-fenyl) -2-pentyl- (3") - 2-(3'-methoxy-phenyl)-2-pentyl-(3")-
pentylamin-(l), pentylamine-(l),
2- (3'-metoksy-f enyl) -2-pentyl- (3") - 2-(3'-methoxy-phenyl)-2-pentyl-(3")-
3-metyl-butylamin- (1), 3-methyl-butylamine-(1),
2- (3'-metoksy-fenyl) -2-pentyl- (3") - 2-(3'-methoxy-phenyl)-2-pentyl-(3")-
3 -metyl-pentylamin- (1), 3 -methyl-pentylamine-(1),
2- (3'-etoksy-fenyl) -2-pentyl- (3") - 2-(3'-ethoxy-phenyl)-2-pentyl-(3")-
butylamin-(l), butylamine-(l),
2- (3'-etoksy-fenyl) -2-pentyl- (3") - 2-(3'-ethoxy-phenyl)-2-pentyl-(3")-
pentylamin-(l), 2 - (3 '-etoksy-f enyl) -2-pentyl-(3 ") - Pentylamine-(1), 2-(3'-ethoxy-phenyl)-2-pentyl-(3")-
3-metyl-butylamin- (1), 3-methyl-butylamine-(1),
2- (3'-etoksy-fenyl) -2-pentyl- (3") - 2-(3'-ethoxy-phenyl)-2-pentyl-(3")-
3-metyl-pentylamin- (1), 3-methyl-pentylamine-(1),
2 - (3' -hy dr oksy -f enyl ) -2 -cy klopentyl - 2 - (3' -hydroxy -phenyl) -2 -cyclopentyl -
butylamin-(l), butylamine-(l),
2- (3'-hydroksy-fenyl) -2-cyklopentyl-pentylamin-(l), 2-(3'-hydroksy-fenyl)-2-cyklopentyl-3-metyl-butylamin- (1), 2-(3'-hydroxy-phenyl)-2-cyclopentyl-pentylamine-(1), 2-(3'-hydroxy-phenyl)-2-cyclopentyl-3-methyl-butylamine-(1),
2- (3'-hydroksy-f enyl) -2-cyklopentyl-3-metyl-pentylamin (1), 2-(3'-hydroxy-phenyl)-2-cyclopentyl-3-methyl-pentylamine (1),
2- (3'-metoksy-f enyl) -2-cyklopentyl-butylamin-(l), 2-(3'-metoksy-fenyl)-2-cyklopentyl-pentylamin-(l), 2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(l), 2-(3'-methoxy-phenyl)-2-cyclopentyl-pentylamine-(l),
2- (3'-metoksy-f enyl) -2-cyklopentyl-3-metyl-butylamin- (1), 2-(3'-methoxy-phenyl)-2-cyclopentyl-3-methyl-butylamine-(1),
2- (3'-metoksy-fenyl) -2-cyklopentyl-3-metyl-pentylamin-(l), 2-(3'-methoxy-phenyl)-2-cyclopentyl-3-methyl-pentylamine-(1),
2- (3'-etoksy-f enyl) -2-cyklopentyl-butylamin-(l), 2-(3'-ethoxy-phenyl)-2-cyclopentyl-butylamine-(1),
2- (3'-etoksy-f enyl) -2-cyklopentyl-pentylamin-(l), 2-(3'-ethoxy-phenyl)-2-cyclopentyl-pentylamine-(1),
2- (3'-etoksy-fenyl) -2-cyklopentyl-3-metyl-butylamin- (1), 2-(3'-ethoxy-phenyl)-2-cyclopentyl-3-methyl-butylamine-(1),
2- (3'-etoksy-fenyl) -2-cyklopentyl-3 -metyl-pentylamin - (1), 2-(3'-ethoxy-phenyl)-2-cyclopentyl-3-methyl-pentylamine - (1),
2- (3'-benzyloksy-fenyl) -2-cyklopentyl-butylamin-(l), 2-(3'-benzyloxy-phenyl)-2-cyclopentyl-butylamine-(1),
2- (3'-benzyloksy-fenyl) -2-cyklopentyl-pentylamin- (1), 2-(3'-benzyloxy-phenyl)-2-cyclopentyl-pentylamine-(1),
2- (3'-benzyloksy-fenyl) -2-cyklopentyl-3-metyl-butylamin-(l) og 2-(3'-benzyloxy-phenyl)-2-cyclopentyl-3-methyl-butylamine-(1) and
2- (3'-benzyloksy-fenyl) -2-cyklopentyl-3-mety 1-pentylamin-(1). 2-(3'-Benzyloxy-phenyl)-2-cyclopentyl-3-methyl-1-pentylamine-(1).
Som ketoner med formel III kan det for eksempel anvendes følgende forbindelser: Aceton, metyletylketon, metylpropylketon, metylbutylketon, metylisopropylketon, metylisobutylketon, dietylketon, dipropylketon, metylvinylketon, isopropyli-denaceton (mesityloksyd), cyklopentanon, cykloheksanon. As ketones with formula III, the following compounds can be used, for example: Acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl isopropyl ketone, methyl isobutyl ketone, diethyl ketone, dipropyl ketone, methyl vinyl ketone, isopropylideneacetone (mesityl oxide), cyclopentanone, cyclohexanone.
De som utgangsstoffer anvendbare aminer med formel II lar seg fordelaktig fremstille ved hydrering av de tilsvarende substituerte cyanider i nærvær av katalysatorer fra det periodiske systems 8. gruppe. Cyanidene er på sin side tilgjen-gelige fra de tilsvarende substituerte ben-zylcyanider ved reaksjon med natrium - amid og alkyl- respektive cyklopentylha-logenider i et med vann ikke blandbart oppløsningsmiddel. The amines of formula II which can be used as starting materials can advantageously be prepared by hydrogenation of the corresponding substituted cyanides in the presence of catalysts from the 8th group of the periodic table. The cyanides, in turn, are available from the corresponding substituted benzyl cyanides by reaction with sodium amide and alkyl-respective cyclopentyl halides in a water-immiscible solvent.
Reduksjonen av et amin med den generelle formel II i nærvær av keton med den generelle formel III kan for eksempel foregå katalytisk ved hjelp av metaller fra det periodiske systems 8. gruppe, for-trinnsvis med palladium-katalysatorer. Omsetningen kan variere innen vide gren-ser og tilpasses de eventuelle forhold. Eksempelvis kan man arbeide i nærvær av et ketonoverskudd som da samtidig tjener som oppløsningsmiddel. Omsetningen foretas hensiktsmessig ved temperaturer inntil 50° C og ved lavere (1,1 ato) eller høy-ere hydrogenovertrykk (inntil 50 ato). Det overskytende keton hydreres ved denne fremgangsmåte ikke til karbinol og kan tilbakevinnes. Man kan imidlertid også arbeide uten anvendelse av ketonoverskudd og anvende et annet egnet oppløs-ningsmiddel, for eksempel metanol. I stedet for palladium kan også nikkelkataly-satorer (Raney-nikkel) finne anvendelse. Likeledes kan man også redusere med nascerende hydrogen, for eksempel alu-miniumamalgam og alkohol, natriumamal-gam, litiumaluminiumhydrid eller na-triumborhydrid. Reduksjonen lar seg også gj ennomføre elektrolytisk. The reduction of an amine with the general formula II in the presence of a ketone with the general formula III can, for example, take place catalytically with the help of metals from the 8th group of the periodic table, preferably with palladium catalysts. The turnover can vary within wide limits and can be adapted to any circumstances. For example, you can work in the presence of an excess of ketones, which then simultaneously serve as a solvent. The conversion is suitably carried out at temperatures up to 50° C and at lower (1.1 ato) or higher hydrogen overpressure (up to 50 ato). The excess ketone is not hydrogenated to carbinol in this process and can be recovered. However, one can also work without using an excess of ketones and use another suitable solvent, for example methanol. Instead of palladium, nickel catalysts (Raney nickel) can also be used. Similarly, one can also reduce with nascent hydrogen, for example aluminum amalgam and alcohol, sodium amalgam, lithium aluminum hydride or sodium borohydride. The reduction can also be carried out electrolytically.
Ifølge en ytterligere fordelaktig ut-førelsesform av fremgangsmåten i følge oppfinnelsen kan man omsette aminer med formel II med estere av uorganiske eller organiske syrer med formel IV. Som så-danne kan det for eksempel anvendes: Isopropyljodid, sekundært butylbromid, 3-brompentan, 2-brom-3-metyl-butan, 2-brom-4-metyl-pentan, cyklopentylbromid, cykloheksyl-bromid, p-toluolsulfonsyre-isopropylester, diisopropylsulfat. According to a further advantageous embodiment of the method according to the invention, amines of formula II can be reacted with esters of inorganic or organic acids of formula IV. As such can be used, for example: Isopropyl iodide, secondary butyl bromide, 3-bromopentane, 2-bromo-3-methyl-butane, 2-bromo-4-methyl-pentane, cyclopentyl bromide, cyclohexyl bromide, p-toluenesulfonic acid isopropyl ester , diisopropyl sulfate.
Omsetningen foregår hensiktsmessig ved oppvarmning av komponentene i et egnet oppløsningsmiddel for eksempel i etanol, isopropanol, benzol, toluol eller xylol ved temperaturer mellom 80—130° C. Oppvarmingens varighet retter seg etter temperaturen og esterkomponentenes re-aksjonsevne og ligger vanligvis mellom en og tyve timer. For å oppfange den dannede syre setter man aminet med formel II hensiktsmessig til i et entil flereganger molart overskudd og anvender et med vann ikke blandbart oppløsningsmiddel hvori det ved omsetningen dannede aminsalt er uoppløselig. I stedet for overskytende amin lar det seg for å oppfange de dannede syrer imidlertid også anvende andre basiske forbindelser, for eksempel natriumbikarbo-nat, vannfritt natriumkarbonat eller ter-tiære aminer som trietylamin eller dietyl-anilin. Omsetningen lar seg også gjen-nomføre uten oppløsningsmiddel ved oppvarmning av de to komponenter ved temperaturer mellom 80 og 130° C idet man hensiktsmessig anvender aminet i dobbelt molart overskudd. The reaction conveniently takes place by heating the components in a suitable solvent, for example in ethanol, isopropanol, benzene, toluene or xylol at temperatures between 80-130° C. The duration of the heating depends on the temperature and the reactivity of the ester components and is usually between one and twenty hours. To capture the acid formed, the amine of formula II is appropriately added in a one to several times molar excess and a water-immiscible solvent is used in which the amine salt formed during the reaction is insoluble. Instead of excess amine, however, other basic compounds can also be used to trap the acids formed, for example sodium bicarbonate, anhydrous sodium carbonate or tertiary amines such as triethylamine or diethylaniline. The reaction can also be carried out without a solvent by heating the two components at temperatures between 80 and 130° C, using the amine in double molar excess appropriately.
En ytterligere utførelsesform består i at man oppvarmer aminer med formel II med alkoholer med formel V i nærvær av Raney-nikkel i lengre tid ved temperaturer mellom 100° C og 120° C. Oppvarmingens varighet er avhengig av det anvendte utgangsstoffs struktur og ligger vanligvis mellom fem og femten timer. A further embodiment consists in heating amines of formula II with alcohols of formula V in the presence of Raney nickel for a longer time at temperatures between 100° C and 120° C. The duration of the heating depends on the structure of the starting material used and is usually between five past fifteen hours.
For fremstilling av fremgangsmåteproduktene i hvis formel substituenten Rs betyr et hydrogenatom fremstilles hensiktsmessig først den tilsvarende alkoksy-eller benzyloksyforbindelse etter en av de angitte metoder. Alkoksyforbindelsen kan deretter på vanlig måte eksempelvis ved oppvarmning med hydrogenklorid, hydro-genbromid, aluminiumklorid eller pyridin-hydroklorid overføres i de tilsvarende hy-droksyforbindelser. Anvender man som utgangsstoffer for fremstilling av fremgangsmåteproduktene benzyloksyforbindelser, for eksempel 2-(3'-benzyloksy-fenyl)-2-cyklopentyl-butylamin-(l), så kan omsetningen enten foretas i ett eller to arbeids-trinn. For the production of the process products in whose formula the substituent Rs means a hydrogen atom, the corresponding alkoxy or benzyloxy compound is suitably prepared first according to one of the specified methods. The alkoxy compound can then be converted in the usual way, for example by heating with hydrogen chloride, hydrogen bromide, aluminum chloride or pyridine hydrochloride, into the corresponding hydroxy compounds. If benzyloxy compounds, for example 2-(3'-benzyloxy-phenyl)-2-cyclopentyl-butylamine-(1), are used as starting materials for the production of the process products, then the reaction can either be carried out in one or two work steps.
Innfører man eksempelvis resten For example, you introduce the rest
inn i en forbindelse med formel I idet man hydrerer et amin med formel II sammen med keton med formel III i nærvær av palladium som katalysatorer, så avspaltes benzylgruppen i samme arbeidsgang. Inn-føres imidlertid resten into a compound of formula I by hydrogenating an amine of formula II together with a ketone of formula III in the presence of palladium as catalysts, then the benzyl group is split off in the same procedure. However, the rest are introduced
etter andre metoder, for eksempel ved om-setning av et amin med formel II med en ester med formel IV så bibeholdes først benzyloksygruppen og kan hvis ønsket gi en ytterligere arbeidsgang, for eksempel avspaltes katalytisk ved hjelp av edelme-taller fra det periodiske systems 8. gruppe som katalysatorer. according to other methods, for example by reacting an amine of formula II with an ester of formula IV, the benzyloxy group is first retained and can, if desired, provide a further work step, for example catalytically split off with the help of noble metal numbers from the periodic table 8 .group as catalysts.
På den annen side kan også, hvis i følge en av de ovenfor nevnte utførelses-former fås fremgangsmåteprodukter i hvis formel R, betyr et hydrogenatom, hydroksygruppen ved alkylering på vanlig måte, for eksempel med dimetylsulfat eller dietylsulfat i alkalisk oppløsning, overfø-res i metoksy- eller etoksygruppen. On the other hand, if, according to one of the above-mentioned embodiments, process products are obtained in whose formula R means a hydrogen atom, the hydroxy group can be transferred by alkylation in the usual way, for example with dimethyl sulfate or diethyl sulfate in alkaline solution, in the methoxy or ethoxy group.
Fremgangsmåteproduktene kan ved behandling med uorganiske eller organiske syrer overføres i de tilsvarende syreaddi-sjonssalter. Eksempelvis kan det for salt-dannelse benyttes følgende fysiologisk tålbare syrer: Uorganiske syrer som halo-genhydrogensyre, spesielt klor- og bromhydrogensyre, svovelsyre, fosforsyre, amid-osulfonsyre, og organiske syrer som eddiksyre, propionsyre, oksalsyre, eplesyre, rav-syre, melkesyre, maleinsyre, fumarsyre, sorbinsyre, citronsyre, acetursyre, aspara-ginsyre, p-amino-benzoesyre, salicylsyre og etylendiamin-tetra-eddiksyre. The process products can be converted into the corresponding acid addition salts by treatment with inorganic or organic acids. For example, the following physiologically tolerable acids can be used for salt formation: Inorganic acids such as hydrohalic acid, especially hydrochloric and bromic acid, sulfuric acid, phosphoric acid, amide osulphonic acid, and organic acids such as acetic acid, propionic acid, oxalic acid, malic acid, succinic acid, lactic acid, maleic acid, fumaric acid, sorbic acid, citric acid, aceturic acid, aspartic acid, p-amino-benzoic acid, salicylic acid and ethylenediamine-tetraacetic acid.
De nye fremgangsmåteprodukters analgetiske virkning kan for eksempel de-monstreres ved brennstrålemetoden ifølge Wolff, Hardy, Goodell, J. Clin. Inv. 19, 659 The analgesic effect of the new method products can, for example, be demonstrated by the burning beam method according to Wolff, Hardy, Goodell, J. Clin. Inv. 19, 659
(1940) på mus. Ifølge denne forsøksanord-ning ble det ved kollektiver av mus under-søkt reaksjonstiden på termisk irritasjon før og etter subkutan applikasjon av pre-paratene. Denne teknikk ble for så vidt modifisert da i en alt eller ingen fremgangsmåte bestemte kriterier ble benyttet for å fastslå prosenttallet for dyrene som reagerer positivt på irritasjonen. Således kunne det finnes meget nøyaktige dosis-virkningsforhold. For N-sek-butyl-2-(3'-hydroksyfenyl)-2-cyklopentyl-butylamin-(l)-hydroklorid ble det etter denne metode ved subkutan applikasjon fastslått den minste virkningsmengde (dosis effec-tiva minima 50) på 0,85 mg/kg. Sammen-ligningsmessig utgjør den minste virkningsmengde av de kjente 2-dimetylami-no-4,4-difenylheptanon (5) -hydroklorid ved subkutan applikasjon 1,5 mg/kg. Prepa-ratet viste seg således ved subkutan applikasjon som dobbelt så sterkt virksomt som det kjente 2-dimetylamino-4,4-dif enyl-heptanon (5) -hydroklorid. (1940) on mice. According to this experimental device, the reaction time to thermal irritation before and after subcutaneous application of the preparations was investigated in groups of mice. This technique was modified to the extent that, in an all-or-none procedure, certain criteria were used to determine the percentage of animals that respond positively to the stimulus. Thus, very precise dose-effect relationships could be found. For N-sec-butyl-2-(3'-hydroxyphenyl)-2-cyclopentyl-butylamine-(1)-hydrochloride, the smallest effective quantity (dosis effec-tiva minima 50) of 0, 85 mg/kg. By way of comparison, the smallest effective amount of the known 2-dimethylamino-4,4-diphenylheptanone (5) hydrochloride by subcutaneous application amounts to 1.5 mg/kg. The preparation thus proved, by subcutaneous application, to be twice as effective as the known 2-dimethylamino-4,4-diphenyl-heptanone (5) hydrochloride.
Den nevnte forbindelse viser en tydelig sedativ virkning på mus som er opp-hisset ved subkutan applikasjon av 1-fenyl-2-metylamino-propan-hydroklorid ved metoden ifølge Ther (Deutsche Apo-theker Zeitung 1953, S. 292). The said compound shows a clear sedative effect on mice which have been agitated by subcutaneous application of 1-phenyl-2-methylamino-propane hydrochloride by the method according to Ther (Deutsche Apo-theker Zeitung 1953, p. 292).
Likeledes kunne det ifølge den av Ther, Vogel og Werner (Arzneimittelfor-schung 9, 351 (1959) ) foreslåtte under-søkelsesmetode på gullhamster såvel ifølge metoden av Vogel og Ther (Arzneimittel-forschung 10, 806 (1960) ) på bomullsrot-ter fastslås en tydelig sedativ neurolep-tisk virkning. Similarly, according to the research method proposed by Ther, Vogel and Werner (Arzneimittelforschung 9, 351 (1959) ) on golden hamsters as well as according to the method of Vogel and Ther (Arzneimittelforschung 10, 806 (1960) ) on cotton roots a clear sedative neuroleptic effect is established.
Toksisitetsundersøkelsene viste at fremgangsmåteproduktene kan anses som ytterliggående uskadelige. Således utgjør for eksempel N-sek. Butyl-2-(3'-hydroksy-f enyl) -2-cyklopentyl-butylamin- (1) -hydroklorid dosis lethalis 50 ved mus i tilfelle intravenøs injeksjon 30 mg/kg, i tilfelle subkutan injeksjon 250 mg/kg og i tilfelle peroral applikasjon 900 mg/kg. Ved undersøkelse på kronisk toksisitet ble det ved peroral applikasjon 900 mg/kg. Ved undersøkelse på kronisk toksisitet ble det ved peroral forfølgelse av samme forbindelse på hunder i 28 dager tålt 10 mg/kg uten patologiske foreteelser i det kliniske bilde og i seksjonsfunn. The toxicity studies showed that the process products can be considered completely harmless. Thus, for example, N-sec. Butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1)-hydrochloride dose lethalis 50 in mice in case of intravenous injection 30 mg/kg, in case of subcutaneous injection 250 mg/kg and in case oral application 900 mg/kg. When examined for chronic toxicity, it was 900 mg/kg with peroral application. In an examination of chronic toxicity, 10 mg/kg was tolerated when the same compound was administered orally to dogs for 28 days without pathological phenomena in the clinical picture and in autopsy findings.
Også ved kliniske undersøkelser viser en N-sek.butyl-2- (3'-hydroksy-fenyl) -2-cyklopentyl-butylamin- (1) -hydroklorid allerede ved en dosering på 2—4 mg en tydelig analgetisk virkning. Also in clinical investigations, an N-sec.butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1)-hydrochloride already shows a clear analgesic effect at a dosage of 2-4 mg.
Fremgangsmåteproduktene kan anvendes som smertestillende middel såvel i fri form som i form av deres addisjonssalter med fysiologisk tålbare syrer, eventuelt i blanding med egnede faste eller flytende farmasøytiske bærestoffer som vann, planteoljer, stivelse, melkesukker eller talkum, eventuelt med hjelpestoffer som stabiliserings-, konserverings- og emulgeringsmidler.. Foretrukne farmasøy-tiske tilberedningsformer er oppløsninger respektive suspensjoner til injeksjon, tab-letter, drageer, kapsler og suppositorier. The method products can be used as pain relievers both in free form and in the form of their addition salts with physiologically tolerable acids, possibly in admixture with suitable solid or liquid pharmaceutical carriers such as water, plant oils, starch, milk sugar or talc, possibly with auxiliaries such as stabilizers, preservatives - and emulsifiers. Preferred pharmaceutical preparation forms are solutions or suspensions for injection, tablets, dragees, capsules and suppositories.
Til parenteral anvendelse kan det anvendes en dosering fra 1 til 20 mg, til oral anvendelse en dosering fra 5 til 50 mg. For parenteral use, a dosage of 1 to 20 mg can be used, for oral use a dosage of 5 to 50 mg.
Fra tysk patent nr. 1.058.063 er det kjent at difenyletylamin-forbindelser har From German patent no. 1,058,063 it is known that diphenylethylamine compounds have
analgetisk virkning. Mens de kjente forbindelser imidlertid er av virkningsstyrke som l-metyl-4-fenyl-piperidin-4-karbon-syreetylesteren, dreier det seg ved produk-tene fremstillet ved fremgangsmåten iføl-ge oppfinnelsen om analgetika som oppnår virkningsstyrkene for 2-dimetylamino-4,4-difenylheptanon-5-hydroklorid (metadon) og også overtreffer dette (fra Liebigs An-nalen der Chemie, bind 561 (1948), side 79 fremgår det at metadon har minst den 5-dobbelte analgetiske virkningsstyrke av pe-tidin). I følgende tabell er det angitt de verdier som er fremkommet ved brenne-strålemetoden ifølge Wolff, Hardy og Goodell på mus for den minste vriknings-mengde av noen fremgangsmåteprodukter sammenlignet med metadon. analgesic effect. While the known compounds are, however, of a potency such as 1-methyl-4-phenyl-piperidine-4-carboxylic acid ethyl ester, the products produced by the method according to the invention are analgesics that achieve the potency of 2-dimethylamino-4 ,4-diphenylheptanone-5-hydrochloride (methadone) and also surpasses this (from Liebig's Annalen der Chemie, volume 561 (1948), page 79 it appears that methadone has at least the 5-fold analgesic potency of pethidine). The following table shows the values obtained by the burning beam method according to Wolff, Hardy and Goodell on mice for the smallest amount of twitching of some process products compared to methadone.
Eksempel 1. Example 1.
N- sek.- butyl- 2-( 3'- metoksy- fenyl) - N-sec.-butyl-2-(3'- methoxy-phenyl)-
2- pentyl-( 3")- butylamin-( 1). 2-pentyl-(3")-butylamine-(1).
30 g 2-(3'-metoksy-fenyl)-2-pentyl-(3")-butylamin-(l) og 150 g metyletylketon hydreres i nærvær av palladium som katalysator ved 50° C inntil avslut-tet hydrogenopptak. Etter adskillelse av katalysator og avdestillering av det overskytende metyletylketon får man N.-sek.-butyl-2- (3'-metoksy-f enyl) -2-pentyl-(3")-butylamin-(l) i kvantitativt utbytte. Det tilsvarende fumarsure salt smelter ved 107° C. 30 g of 2-(3'-methoxy-phenyl)-2-pentyl-(3")-butylamine-(1) and 150 g of methyl ethyl ketone are hydrogenated in the presence of palladium as a catalyst at 50° C until complete hydrogen uptake. After separation of catalyst and distilling off the excess methyl ethyl ketone gives N-sec-butyl-2-(3'-methoxy-phenyl)-2-pentyl-(3")-butylamine-(1) in quantitative yield. The corresponding fumaric acid salt melts at 107° C.
Det som utgangsstoff tjenende 2-(3'-metoksy-fenyl) -2-pentyl- (3") -butylamin-(1) med kokepunkt ved 3 mm hg 148—152° C får man ved hydrering av (3-metoksy-f enyl) -etyl-pentyl- (3') -acetonitril (kokepunkt ved 6 mm hg 148—150° C) som kan fremstilles fra (3-metoksy-fenyl)-etyl-acetonitril ved reaksjon med natriumamid og 3-brom-pentan. The starting material 2-(3'-methoxy-phenyl)-2-pentyl-(3")-butylamine-(1) with a boiling point at 3 mm hg 148-152° C is obtained by hydrogenation of (3-methoxy- phenyl)-ethyl-pentyl-(3')-acetonitrile (boiling point at 6 mm hg 148-150° C) which can be prepared from (3-methoxy-phenyl)-ethyl-acetonitrile by reaction with sodium amide and 3-bromo- pentane.
Eksempel 2. Example 2.
N- sek. butyl- 2-( 3'- hydroksy- f enyl) - N- sec. butyl-2-(3'-hydroxy-phenyl)-
2- pentyl- ( 3")- butylamin-( 1). 2-pentyl-(3")-butylamine-(1).
Ved åtte timers oppvarmning av N-sek.-butyl-2- (3'-metoksy-f enyl) -2-pentyl-(3")-butylamin-(l) med 48 pst. bromhydrogensyre under tilbakeløp avspaltes metylgruppen. Man får i kvantitativt utbytte N-sek.butyl-2- (3'-hydroksy-f enyl) - 2-pentyl-(3")-butylamin-(l) som danner et fumarat med smeltepunkt 167° C. By heating N-sec-butyl-2-(3'-methoxy-phenyl)-2-pentyl-(3")-butylamine-(l) with 48% hydrobromic acid under reflux for eight hours, the methyl group is split off. You get in quantitative yield N-sec.butyl-2-(3'-hydroxy-phenyl)-2-pentyl-(3")-butylamine-(1) which forms a fumarate with melting point 167° C.
Eksempel 3. Example 3.
N- isopropyl- 2- ( 3'- metoksy- fenyl) - 2- cyklopentyl- butylamin-( 1). N-isopropyl-2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1).
a) 20 g 2-(3'-metoksy-fenyl)-2-cyklopentyl-butylamin-(1) hydreres i 100 g aceton a) 20 g of 2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1) are hydrated in 100 g of acetone
tilsvarende den forskrift som er angitt i Eksempel 1. Man får i kvantitativt utbytte N-isopropyl-2- (3'-metoksy-fenyl) -2-cyklopentyl-butylamin-(l) hvis hydroklorid smelter ved 145° C. corresponding to the regulation stated in Example 1. N-isopropyl-2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1) whose hydrochloride melts at 145° C is obtained in quantitative yield.
b) Den samme forbindelse får man ved 15 timers oppvarmning av 2-^'-metoksy-fenyl) -2-cyklopentyl-butylamin- (1) med b) The same compound is obtained by heating 2-['-methoxy-phenyl)-2-cyclopentyl-butylamine- (1) for 15 hours with
overskytende isopropanol og meget Raney-nikkel ved 100° C. c) Den samme forbindelse får man ved 3 timers oppvarmning av 2-(3'-metoksy-fenyl)-2-cyklopentyl-butyl-amin-(l) med 1 mol diisopropylsulfat ved 100° C. excess isopropanol and a lot of Raney nickel at 100° C. c) The same compound is obtained by heating 2-(3'-methoxy-phenyl)-2-cyclopentyl-butyl-amine-(l) with 1 mol of diisopropyl sulfate for 3 hours at 100°C.
Eksempel 4. Example 4.
N- sek. butyl- 2-( 3'- metoksy- f enyl) - 2- cyklopentyl- butylamin-( 1). N- sec. butyl-2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1).
a) 300 g 2-(3'-metoksy-f enyl) -2-cyklopentyl-butylamin- (1) hydreres i 750 g metyletylketon tilsvarende den forskrift som er angitt i eksempel 1. Man får i kvantitativt utbytte N-sek.butyl-2-^'-metoksy-fenyl) -2-cyklopentyl-butylamin- (1) hvis a) 300 g of 2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine- (1) is hydrogenated in 750 g of methyl ethyl ketone corresponding to the regulation stated in example 1. N-sec.butyl is obtained in quantitative yield -2-^'-methoxy-phenyl)-2-cyclopentyl-butylamine- (1) if
hydroklorid smelter ved 185° C. hydrochloride melts at 185°C.
b) Den samme forbindelse får man når man hydrerer 2-(3'-metoksy-fenyl)-2-cyklopentyl-butylamin-(1) med metylvinylketon og palladium som katalysator ved 50° C til avslutning av hydrogenopptak. Det som utgangsstoff tjenende 2-(3'-metoksy-fenyl)-2-cyklopentyl-butylamin-(1) med kokepunkt ved 5 mm hg 174 —176° C får man ved hydrering av (3-metoksy-fenyl) -etyl-cyklopentyl-acetonitril (kokepunkt ved 3 mm hg 154— 156° C) som kan fremstilles av (3-metoksy-fenyl)-etyl-acetonitril ved reaksjon med natriumamid og cyklopentylbromid. b) The same compound is obtained when 2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1) is hydrogenated with methyl vinyl ketone and palladium as catalyst at 50° C to complete hydrogen absorption. The starting material 2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1) with a boiling point at 5 mm hg 174 —176° C is obtained by hydrogenation of (3-methoxy-phenyl)-ethyl- cyclopentyl acetonitrile (boiling point at 3 mm hg 154-156° C) which can be prepared from (3-methoxy-phenyl)-ethyl acetonitrile by reaction with sodium amide and cyclopentyl bromide.
Eksempel 5— 9. Example 5— 9.
Etter den i eksempel 1 angitte fremgangsmåte ble det fra 2-(3'-metoksy-f enyl) -2-cyklopentyl-butyl-amin- (1) ved hydrering med ketoner dannet følgende forbindelser: 5) Med metylisopropylketon N-[3"-me-tyl-butyl- (2") ] -2- (3'-metoksy-f enyl) - 2-cyklopentyl-butylamin- (1), hydroklori- Following the procedure stated in example 1, the following compounds were formed from 2-(3'-methoxy-phenyl)-2-cyclopentyl-butyl-amine- (1) by hydrogenation with ketones: 5) With methylisopropyl ketone N-[3" -methyl-butyl-(2")] -2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(1), hydrochloride-
dets smeltepunkt 131° C. its melting point 131° C.
6) Med metylpropylketon N-pentyl-(2")- 6) With methylpropyl ketone N-pentyl-(2")-
2- (3'-metoksy-fenyl) -2-cyklopentyl- 2-(3'-methoxy-phenyl)-2-cyclopentyl-
butylamin-(1), hydrokloridets smeltepunkt 200° C. 7) Med dietylketon N-pentyl-(3")-2-(3'-metoksy-fenyl-2-cyklopentyl-butylamin- butylamine-(1), the melting point of the hydrochloride 200° C. 7) With diethyl ketone N-pentyl-(3")-2-(3'-methoxy-phenyl-2-cyclopentyl-butylamine-
(1), hydrokloridets smeltepunkt 155° C. (1), the melting point of the hydrochloride 155° C.
8) Med cyklopentanon N-cyklopentyl-2-(3'-metoksy-fenyl)-2-cyklopentyl-butylamin-(l), hydrokloridets smeltepunkt 230° C. 9) Med cykloheksanon N-sykloheksyl-2-(3'-metoksyf enyl)-2-cyklopentyl-butylamin - (1) -hydrokloridets smeltepunkt 195° C. 8) With cyclopentanone N-cyclopentyl-2-(3'-methoxy-phenyl)-2-cyclopentyl-butylamine-(l), melting point of the hydrochloride 230° C. 9) With cyclohexanone N-cyclohexyl-2-(3'-methoxy enyl)-2-cyclopentyl-butylamine - (1) -hydrochloride melting point 195° C.
Eksemplene 10— 16. Examples 10-16.
Ved 8 timers oppvarmning av de i ek- During 8 hours of heating of those in the
semplene 3 til 9 beskrevne 3-metoksyfor- examples 3 to 9 described 3-methoxyfor-
bindelser med 48 pst.-ig bromhydrogensyre under tilbakeløp avspaltes metylgruppene under dannelse av de tilsvarende hydrok-syfenylderivater. På denne måte ble føl- bonds with 48% hydrobromic acid under reflux, the methyl groups are split off to form the corresponding hydroxyphenyl derivatives. In this way, the follow-
gende fremgangsmåteprodukter fremstil- manufacturing process products
let: easy:
10) N-isopropyl-2-(3'-hydroksy-fenyl)-2-cyklo-pentyl-butylamin- (1), hydroklori- 10) N-isopropyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1), hydrochloride
dets smeltepunkt 206° C. its melting point 206° C.
Ila) N-sek.butyl-2- (3'-hydroksy-f enyl) - 2-cyklo-pentyl-butylamin- (1), hydroklori- Ila) N-sec.butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1), hydrochloride
dets smeltepunkt 178° C. its melting point 178° C.
11b) Den samme forbindelse fås også når man hydrerer 2-(3'-hydroksy-fenyl)-2-cyklopentyl-butylamin-(l), som var dan- 11b) The same compound is also obtained when one hydrates 2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1), which was dan-
net ved avmetylering av den tilsvarende metoksyforbindelse med 48 pst.'ig brom- net by demethylation of the corresponding methoxy compound with 48 percent bromine
hydrogensyre og danner et fumarat med smeltepunkt 150° C, med metyletylketon og palladium som katalysator ved 50° C. 12) N-[3"-metyl-butyl-(2")]-2-(3'-hydroksy-fenyl)-2-cyklopentyl-butylamin- hydrogen acid and forms a fumarate with a melting point of 150° C, with methyl ethyl ketone and palladium as a catalyst at 50° C. 12) N-[3"-methyl-butyl-(2")]-2-(3'-hydroxy-phenyl) -2-cyclopentyl-butylamine-
(1), hydrokloridets smeltepunkt 164° C. (1), the melting point of the hydrochloride 164° C.
13) N-pentyl-(2")-2-(3'-hydroksy-fenyl) -2-cyklopentyl-butylamin- (1), hy- 13) N-pentyl-(2")-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine- (1), hy-
drokloridets smeltepunkt 212° C . the drochloride's melting point 212° C .
14) N-pentyl-(3")-2-(3'-hydroksy- 14) N-pentyl-(3")-2-(3'-hydroxy-
fenyl) -2-cyklopentyl-butylamin- (1), hy- phenyl) -2-cyclopentyl-butylamine-(1), hy-
drokloridets smeltepunkt 184° C. the melting point of the hydrochloride 184° C.
15) N-cyklopentyl-2- (3'-hydroksy-f enyl) -2-cyklopentyl-butylamin- (1), hy- 15) N-cyclopentyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1), hy-
drokloridets smeltepunkt 209° C. the melting point of the drochloride 209° C.
16) N-cykloheksyl-2- (3'-hydroksy-f enyl) -2-cyklo-pentyl-butylamin- (1), hy- 16) N-cyclohexyl-2-(3'-hydroxy-phenyl)-2-cyclo-pentyl-butylamine-(1), hy-
drokloridets smeltepunkt 236° C. drochloride's melting point 236° C.
17) N-sek.butyl-2- (3'-etoksy-fenyl) -2-cyklopentyl-butylamin-(l) får man ved 17) N-sec.butyl-2-(3'-ethoxy-phenyl)-2-cyclopentyl-butylamine-(1) is obtained by
innvirkning av dietylsulfat i alkalisk opp- impact of diethyl sulfate in alkaline up-
løsning på N-sek.butyl-2-(3'-hydroksy-f enyl) -2-cyklopentyl-butylamin- (1), som fås ifølge eksempel 11. solution of N-sec.butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-butylamine-(1), which is obtained according to example 11.
Eksempel 18. Example 18.
N- sek. butyl- 2-( Z'- metoksy- fenyl) - 2- cyklopentyl- pentylamin-( 1). N- sec. butyl-2-(Z'-methoxy-phenyl)-2-cyclopentyl-pentylamine-(1).
16 g 2-(3'-metoksy-fenyl)-2-cyklopentyl-pentylamin-(l) hydreres i 150 g metyl- 16 g of 2-(3'-methoxy-phenyl)-2-cyclopentyl-pentylamine-(1) are hydrated in 150 g of methyl-
etylketon tilsvarende den forskrift som er angitt i eksempel 1 og opparbeides. Man får i kvantitativt utbytte N-sek.butyl-2-(3'-metoksy-fenyl)-2-cyklopentyl-pentyl- ethyl ketone corresponding to the regulation stated in example 1 and worked up. One obtains in quantitative yield N-sec.butyl-2-(3'-methoxy-phenyl)-2-cyclopentyl-pentyl-
amin-(l), hvis hydroklorid smelter ved 127° C. amine-(l), whose hydrochloride melts at 127° C.
Det som utgangsstoff tjenende 2-(3'-metoksy-fenyl)-2-cyklopentyl-pentyl- The starting material 2-(3'-methoxy-phenyl)-2-cyclopentyl-pentyl-
amin-(l), med kokepunkt ved 5 mm hg 178—180° C får man ved hydrering av (3-metoksy-fenyl)-propyl-cyklopentyl- amine-(l), with boiling point at 5 mm hg 178-180° C is obtained by hydrogenation of (3-methoxy-phenyl)-propyl-cyclopentyl-
acetonitril (kokepunkt ved 5 mm hg 168— acetonitrile (boiling point at 5 mm hg 168—
170° C). Sistnevnte forbindelse kan frem- 170°C). The latter connection can produce
stilles av 3-metoksybenzylcyanid, natrium- is produced by 3-methoxybenzyl cyanide, sodium
amid og propylbromid og etterfølgende om- amide and propyl bromide and subsequent re-
setning av det dannede (3-metoksy-fenyl)-propyl-acetonitril (kokepunkt ved 5 mm hg 134—135° C) med natriumamid og cyklopentylbromid. reaction of the formed (3-methoxy-phenyl)-propyl-acetonitrile (boiling point at 5 mm hg 134-135° C) with sodium amide and cyclopentyl bromide.
Eksempel 19. Example 19.
N- sek. butyl- 2- ( 3'- hydroksy- fenyl) - 2- cyklopentyl- pentylamin-( 1). N- sec. butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-pentylamine-(1).
Ved 8 timers oppvarmning av N-sek.-butyl-2 - (3 '-metoksy-fenyl) -2 -cy klopen- Upon 8-hour heating of N-sec.-butyl-2-(3'-methoxy-phenyl)-2-cyclopene-
tylamin-(l) med 48 pst.'ig bromhydrogen- tylamine-(l) with 48 percent hydrogen bromide
syre under tilbakeløp avspaltes metylgrup- acid during reflux, the methyl group is split off
pen. Man får i kvantitativt utbytte N-sek.- pretty. One gets in quantitative yield N-sec.-
butyl-2- (3'-hydroksy-fenyl) -2-cyklopentyl-pentylamin-(1), hvis hydroklorid smelter ved 228° C. butyl-2-(3'-hydroxy-phenyl)-2-cyclopentyl-pentylamine-(1), whose hydrochloride melts at 228°C.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7528951A FR2324305A2 (en) | 1975-09-22 | 1975-09-22 | NEW DERIVATIVES OF ISOINDOLINE, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
Publications (3)
Publication Number | Publication Date |
---|---|
NO763225L NO763225L (en) | 1977-03-23 |
NO145098B true NO145098B (en) | 1981-10-05 |
NO145098C NO145098C (en) | 1982-01-13 |
Family
ID=9160275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO763225A NO145098C (en) | 1975-09-22 | 1976-09-21 | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOINDOLIN DERIVATIVES. |
Country Status (26)
Country | Link |
---|---|
JP (2) | JPS5239700A (en) |
AR (1) | AR209515A1 (en) |
AT (1) | AT349024B (en) |
AU (1) | AU502308B2 (en) |
BE (1) | BE846409R (en) |
CH (2) | CH617696A5 (en) |
CS (1) | CS196323B2 (en) |
DD (1) | DD126905A6 (en) |
DE (1) | DE2642598A1 (en) |
DK (1) | DK142365B (en) |
ES (1) | ES451741A2 (en) |
FI (1) | FI59595C (en) |
FR (1) | FR2324305A2 (en) |
GB (1) | GB1498348A (en) |
HU (1) | HU176005B (en) |
IE (1) | IE43551B1 (en) |
LU (1) | LU75838A1 (en) |
MX (1) | MX3641E (en) |
NL (1) | NL7610201A (en) |
NO (1) | NO145098C (en) |
PH (1) | PH12289A (en) |
PL (2) | PL110655B1 (en) |
SE (1) | SE423391B (en) |
SU (1) | SU671724A3 (en) |
YU (1) | YU230476A (en) |
ZA (1) | ZA765589B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282532C (en) * | 1986-08-22 | 1991-04-02 | Myron Timothy Maxson | Organosiloxane inhibitors for hydrosilation reactions and polyorganosiloxane compositions containing same |
US6739238B2 (en) | 2000-11-20 | 2004-05-25 | Nissan Motor Co., Ltd. | Sliding structure for a reciprocating internal combustion engine and a reciprocating internal combustion engine using the sliding structure |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA04700A (en) * | 1973-05-15 | 1980-07-31 | Rhone Poulenc Sa | New derivatives of naphthyridine and their preparation process. |
-
1975
- 1975-09-22 FR FR7528951A patent/FR2324305A2/en active Granted
-
1976
- 1976-08-24 PH PH18826A patent/PH12289A/en unknown
- 1976-09-14 NL NL7610201A patent/NL7610201A/en not_active Application Discontinuation
- 1976-09-17 SU SU762403396A patent/SU671724A3/en active
- 1976-09-17 GB GB38671/76A patent/GB1498348A/en not_active Expired
- 1976-09-17 AU AU17893/76A patent/AU502308B2/en not_active Expired
- 1976-09-17 IE IE2064/76A patent/IE43551B1/en unknown
- 1976-09-17 ZA ZA765589A patent/ZA765589B/en unknown
- 1976-09-17 JP JP51110948A patent/JPS5239700A/en active Pending
- 1976-09-20 MX MX764932U patent/MX3641E/en unknown
- 1976-09-20 PL PL1976209687A patent/PL110655B1/en unknown
- 1976-09-20 PL PL1976192537A patent/PL111060B1/en unknown
- 1976-09-20 AR AR264772A patent/AR209515A1/en active
- 1976-09-20 YU YU02304/76A patent/YU230476A/en unknown
- 1976-09-21 DK DK425076AA patent/DK142365B/en not_active IP Right Cessation
- 1976-09-21 BE BE170795A patent/BE846409R/en not_active IP Right Cessation
- 1976-09-21 HU HU76RO900A patent/HU176005B/en unknown
- 1976-09-21 LU LU75838A patent/LU75838A1/xx unknown
- 1976-09-21 NO NO763225A patent/NO145098C/en unknown
- 1976-09-21 DD DD194904A patent/DD126905A6/xx unknown
- 1976-09-21 CH CH1196276A patent/CH617696A5/en not_active IP Right Cessation
- 1976-09-21 SE SE7610477-7A patent/SE423391B/en not_active IP Right Cessation
- 1976-09-21 CS CS766117A patent/CS196323B2/en unknown
- 1976-09-22 ES ES451741A patent/ES451741A2/en not_active Expired
- 1976-09-22 FI FI762699A patent/FI59595C/en not_active IP Right Cessation
- 1976-09-22 DE DE19762642598 patent/DE2642598A1/en not_active Ceased
- 1976-09-22 AT AT702476A patent/AT349024B/en not_active IP Right Cessation
-
1979
- 1979-09-04 CH CH796279A patent/CH617935A5/en not_active IP Right Cessation
-
1984
- 1984-10-09 JP JP59210605A patent/JPS6038392B2/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1275069B (en) | 1- (3 ', 5'-dihydroxyphenyl) -1-hydroxy-2-isopropylaminoalkanes and processes for their preparation | |
US4069223A (en) | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof | |
US20040204453A1 (en) | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | |
DE1770595C3 (en) | 2- (N-isopropylaminomethyl) -7-nitro-1,2,3,4-tetrahydroquinoline derivatives and their pharmaceutically acceptable acid addition salts | |
US3202711A (en) | Nu-substituted phenalkyl amines | |
US4000143A (en) | Substituted piperidines | |
US4010202A (en) | 5,6-Dihydroxy aminotetralol compounds | |
US2852526A (en) | Substituted pyrrolidines | |
NO145098B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE ISOINDOLIN DERIVATIVES | |
US3043844A (en) | Lower-alkyl 1-[3-(monocarbocyclic-aryl)-2-propenyl]-4-phenyl-4-piperidyl ketones and their preparation | |
IL32481A (en) | Diphenylmethoxyethylamino derivatives,their preparation and pharmaceutical compositions containing them | |
EP0237169B1 (en) | 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates | |
US3963727A (en) | 1,2 Disubstituted benzimidazole derivatives | |
CH624104A5 (en) | ||
EP0052311A1 (en) | 1-((Benzoylphenyl) - lower-alkyl) piperidines and carbinol analogs and preparation thereof | |
DE2210154C2 (en) | 2- (o-Acylaminophenäthyl) -1-alkylpiperidines, process for their preparation and pharmaceuticals containing them | |
DE2061864B2 (en) | Acyl derivatives of substituted bis-arylalkylamines | |
US3202674A (en) | Phenethylamine derivatives | |
NO142103B (en) | EQUIPMENT FOR USE IN AND ON AGRICULTURAL PRODUCTS | |
DE2556143A1 (en) | 9-AMINOALKYL-9,10-DIHYDRO-9,10-METHANOANTHRACENE | |
DE1493961C3 (en) | l-Hydroxy-2-alkylamino-l-phenyläthanderivate their acid addition salts, process for their production and pharmaceutical preparations | |
US4104402A (en) | 5,6-Dihydroxy aminotetralol compounds | |
CA1041546A (en) | Propanol derivatives | |
US2513698A (en) | 2 (3) benxofuranone derivatives and methods of making them | |
DD149664A5 (en) | PROCESS FOR PRODUCING 1,1'-BIPHENYL-2-YL-ALKYLAMINE DERIVATIVES |